PRAX Praxis Precision Medicines, Inc.
Pharmaceutical Preparations · Nasdaq · SEC CIK 1689548 · Fiscal year ends 12/31
Financial factors as of 2025-09-30 (2025Q3), TTM = sum of the last four quarters
Growth
TTM revenue YoY365.0%
TTM net income YoY-80.8%
TTM EPS YoY-41.4%
Revenue 3-yr CAGR—
Net income 3-yr CAGR—
Margins
Gross margin—
Operating margin-3,927.5%
Net margin-3,658.5%
FCF margin-3,067.4%
EBITDA margin-3,925.4%
Returns
ROE-75.2%
ROA-67.2%
ROIC (approx.)-113.5%
Asset turnover0.02x
Leverage & solvency
Liabilities / assets13.3%
Debt / equity0.00x
Current ratio5.18x
Interest coverage—
Cash quality & payout
Operating cash flow / net income0.84x
Accruals ratio-10.9%
Payout ratio—
Capex / revenue0.8%
Factor history charts and full statement history on Pro 🔒
Financial statements
| Line item | 2026Q32026-09-30 | 2026Q22026-06-30 | 2026Q12026-03-31 | 2025Q4*2025-12-31 | 2025Q32025-09-30 | 2025Q22025-06-30 | 2025Q12025-03-31 | 2024Q4*2024-12-31 |
|---|---|---|---|---|---|---|---|---|
| Income statement | ||||||||
| Revenue | — | — | — | $0 | $0 | $0 | $0 | $7.46M |
| R&D expense | $64.20M | $69.42M | $77.99M | $77.51M | $65.80M | $63.01M | $60.81M | $56.29M |
| SG&A expense | $42.71M | $27.49M | $27.87M | $19.54M | $12.56M | $13.06M | $13.92M | $15.13M |
| Operating income | -$106.91M | -$96.90M | -$105.86M | -$97.04M | -$78.36M | -$76.07M | -$74.73M | -$63.96M |
| Net income | -$94.23M | -$83.72M | -$92.56M | -$88.91M | -$73.93M | -$71.13M | -$69.30M | -$58.68M |
| EBITDA | -$106.88M | -$96.87M | -$105.82M | -$97.02M | -$78.34M | -$76.02M | -$74.68M | -$63.91M |
| EPS (basic) | -3.23 | -2.87 | -3.20 | — | -3.36 | -3.31 | -3.29 | — |
| EPS (diluted) | -3.23 | -2.87 | -3.20 | — | -3.36 | -3.31 | -3.29 | — |
| Weighted avg. shares (diluted) | 29.18M | 29.13M | 28.88M | — | 21.98M | 21.47M | 21.06M | — |
| Balance sheet | ||||||||
| Cash & equivalents | $361.85M | $474.76M | $536.33M | $357.33M | $149.53M | $157.41M | $165.57M | $215.79M |
| Short-term investments | $383.47M | $283.79M | $250.53M | $242.00M | $117.63M | $143.86M | $162.42M | $177.19M |
| Current assets | $762.80M | $771.90M | $797.77M | $610.91M | $273.84M | $306.58M | $333.57M | $404.37M |
| PP&E, net | $1.90M | $492,000 | $170,000 | $147,000 | $174,000 | $258,000 | $247,000 | $230,000 |
| Intangibles | — | $773,000 | — | $0 | — | — | — | — |
| Total assets | $1.31B | $1.39B | $1.46B | $937.91M | $396.39M | $452.83M | $478.74M | $483.11M |
| Current liabilities | $52.50M | $49.06M | $50.24M | $59.77M | $52.88M | $48.61M | $39.52M | $37.55M |
| Total liabilities | $52.50M | $49.06M | $50.24M | $59.77M | $52.88M | $48.61M | $39.52M | $37.66M |
| Shareholders' equity | $1.26B | $1.34B | $1.41B | $878.14M | $343.50M | $404.22M | $439.21M | $445.45M |
| Shares outstanding | 27.95M | 27.92M | 27.86M | 25.20M | 21.17M | 21.04M | 20.34M | 19.42M |
| Cash flow statement | ||||||||
| Operating cash flow | -$81.74M | -$77.54M | -$86.15M | -$76.33M | -$65.06M | -$54.68M | -$53.01M | -$56.12M |
| Capital expenditure | $1.55M | $245,000 | $62,000 | $0 | $0 | $56,000 | $0 | $0 |
| Free cash flow | -$83.29M | -$77.79M | -$86.21M | -$76.33M | -$65.06M | -$54.73M | -$53.01M | -$56.12M |
| Investing cash flow | -$32.10M | $10.98M | -$344.27M | -$328.39M | $50.41M | $17.89M | -$51.06M | -$10.92M |
| Financing cash flow | $929,000 | $4.57M | $609.43M | $612.52M | $6.76M | $28.63M | $54.27M | $113.77M |
| Depreciation & amortization | $33,000 | $33,000 | $39,000 | $28,000 | $19,000 | $46,000 | $47,000 | $47,000 |
| Stock-based compensation | $14.89M | $11.31M | $17.11M | $9.94M | $7.45M | $7.77M | $8.79M | $8.57M |
Free plan shows the latest 8 periods; Pro shows all 29 🔒
· This company does not report gross profit in XBRL.
· Most companies do not report Q4 separately: Q4 = full year − first three quarters (marked *). EPS and share counts cannot be subtracted, so Q4 EPS is often blank; cash flow statements are year-to-date in quarterly reports, so single quarters are mostly derived.
· No price-based ratios such as P/E or P/B (the site uses no licensed market data). Blanks are shown as —.
Source: SEC EDGAR XBRL (financial statements filed with the SEC), updated 2026-11-20 06:27.